Business Standard

Sunday, December 22, 2024 | 05:03 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Volume IconCoronavirus vaccine: Things to know about process, timeline & effectiveness

Sources revealed, data from the global trials would be submitted to the Indian regulator by the end of December

ImageKanishka Gupta New Delhi
A healthcare worker prepares specimen collection tubes at a coronavirus disease (COVID-19) drive-thru testing location in Houston, Texas. Photo: Reuters

Photo: Reuters

After Pfizer and Moderna, the much anticipated AstraZeneca-Oxford vaccine candidate has shown positive results in an interim analysis of clinical trials in the UK and Brazil, with a vaccine efficacy of up to 90 per cent in different dosing regimens.
 
Sources revealed, data from the global trials would be submitted to the Indian regulator by the end of December, and Serum Institute of India (SII), AstraZeneca’s manufacturing partner here, would submit the interim data from the Indian arm by then. 

Tune in for more











Track Title by Scott Buckley – www.scottbuckley.com.au

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 24 2020 | 1:45 PM IST